JPH08245694A - Vasodepressor substance and zein capable of being easily degraded with protease and used as its production intermediate and their production - Google Patents
Vasodepressor substance and zein capable of being easily degraded with protease and used as its production intermediate and their productionInfo
- Publication number
- JPH08245694A JPH08245694A JP7077162A JP7716295A JPH08245694A JP H08245694 A JPH08245694 A JP H08245694A JP 7077162 A JP7077162 A JP 7077162A JP 7716295 A JP7716295 A JP 7716295A JP H08245694 A JPH08245694 A JP H08245694A
- Authority
- JP
- Japan
- Prior art keywords
- zein
- urea
- protease
- protein
- denaturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002494 Zein Polymers 0.000 title claims abstract description 74
- 239000005019 zein Substances 0.000 title claims abstract description 74
- 229940093612 zein Drugs 0.000 title claims abstract description 74
- 239000000126 substance Substances 0.000 title claims abstract description 21
- 239000004365 Protease Substances 0.000 title claims abstract description 11
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 10
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 230000002541 vasodepressive effect Effects 0.000 title abstract 3
- 239000003071 vasodilator agent Substances 0.000 title abstract 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000004202 carbamide Substances 0.000 claims abstract description 30
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 108090001109 Thermolysin Proteins 0.000 claims abstract description 18
- 238000002523 gelfiltration Methods 0.000 claims abstract description 15
- 238000000354 decomposition reaction Methods 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000002255 enzymatic effect Effects 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000003398 denaturant Substances 0.000 claims description 5
- 208000001953 Hypotension Diseases 0.000 claims description 4
- 208000021822 hypotensive Diseases 0.000 claims description 4
- 230000001077 hypotensive effect Effects 0.000 claims description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 24
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 102000004190 Enzymes Human genes 0.000 abstract description 11
- 108090000790 Enzymes Proteins 0.000 abstract description 11
- 235000013305 food Nutrition 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 abstract description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 abstract description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 abstract description 6
- 235000013402 health food Nutrition 0.000 abstract description 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract description 4
- 240000008042 Zea mays Species 0.000 abstract description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract description 4
- 235000005822 corn Nutrition 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000000638 solvent extraction Methods 0.000 abstract description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract 3
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000003297 denaturating effect Effects 0.000 abstract 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000000926 separation method Methods 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 238000009835 boiling Methods 0.000 description 6
- 239000007857 degradation product Substances 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 101710180012 Protease 7 Proteins 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【0001】[0001]
【0002】本発明は、血圧降下物質とその製造用中間
体であるプロテアーゼ易分解性ゼイン及びそれらの製造
方法に関する。The present invention relates to an antihypertensive substance, a protease-degradable zein which is an intermediate for producing the same, and a process for producing them.
【0003】本発明に係る血圧降下物質は、高血圧の予
防、および治療のために医薬品、食品、健康食品として
利用可能である。The blood pressure lowering substance according to the present invention can be used as a medicine, food or health food for the prevention and treatment of hypertension.
【0004】[0004]
【0005】血圧の調節には、いくつかの機構がある。There are several mechanisms for controlling blood pressure.
【0006】その一つレニン-アンギオテンシン系で
は、肝臓から分泌されるアンギオテンシンノーゲンが腎
臓に存在するレニンによってアンギオテンシン-Iとな
り、アンギオテンシン-Iは血中のアンギオテンシン変換
酵素(以下ACEと略称)によってアンギオテンシン-I
Iに変換される。In the renin-angiotensin system, angiotensin nogen secreted from the liver is converted into angiotensin-I by renin existing in the kidney, and angiotensin-I is angiotensin-converting enzyme (hereinafter abbreviated as ACE) in the blood. I
Converted to I.
【0007】アンギオテンシン-IIは強力な昇圧ペプチ
ドであり、血管平滑筋を収縮させて血圧を上昇させる。Angiotensin-II is a potent pressor peptide, which contracts vascular smooth muscle and raises blood pressure.
【0008】また、ACEはカリクレイン-キニン系に
も作用し、降圧性のブラジキニンを分解して血圧の上昇
に作用する。[0008] ACE also acts on the kallikrein-quinine system and decomposes the antihypertensive bradykinin to increase blood pressure.
【0009】このACEを阻害することによって、血圧
の上昇抑制が可能である。By inhibiting this ACE, the rise in blood pressure can be suppressed.
【0010】ACE阻害剤としては、カプトプリルなど
が医薬品として実用化されている。As the ACE inhibitor, captopril and the like have been put into practical use as pharmaceuticals.
【0011】また、ACE阻害剤として、多くの薬品、
高度に精製されたペプチド、食品などが報告されてい
る。Further, many drugs as ACE inhibitors,
Highly purified peptides and foods have been reported.
【0012】しかし、食品としては高度に精製されたペ
プチドは実用的ではなく、単に食品または健康食品とし
て報告されたものはその効果が弱かったり持続性がない
等、疑問のあるものが多い。[0012] However, highly purified peptides are not practical as foods, and there are many doubtful ones such as those merely reported as foods or health foods, because their effects are weak or not long-lasting.
【0013】従来のACE阻害ペプチドは、蛋白分解物
を高度に精製したものやアミノ酸から合成したものが殆
どである。Most of the conventional ACE-inhibiting peptides are those obtained by highly purifying proteolytic products and those synthesized from amino acids.
【0014】これらはコストの面からも食品としての実
用性は少ないものであった。From the viewpoint of cost, these were not practical as foods.
【0015】また、大豆や小麦などからいくつかの血圧
降下物質が得られており、医薬品および食品として報告
されているが、十分な効果を示すものは見あたらない。Further, some blood pressure-lowering substances have been obtained from soybean, wheat and the like, and they have been reported as pharmaceuticals and foods, but none showing sufficient effects have been found.
【0016】例えば、特開平2−240028号公報に
は、血圧降下剤として、ゼインのサーモライシン加水分
解物が記載されている。[0016] For example, Japanese Patent Application Laid-Open No. 2-240028 describes a thermolysin hydrolyzate of zein as a blood pressure lowering agent.
【0017】[0017]
【0018】しかしながら、上記の特開平2−2400
28号公報に記載の血圧降下剤は、ゼインが水に溶け
ず、ゼインの分解に時間がかかることから、工業的生産
に適したものではない。However, the above-mentioned Japanese Patent Laid-Open No. 2-2400
The antihypertensive agent described in Japanese Patent No. 28 is not suitable for industrial production because zein does not dissolve in water and it takes time to decompose zein.
【0019】従って、本発明の目的は、医薬品、食品、
または健康食品として安全かつ実用的でACE阻害効果
を有し、工業的生産に適した血圧降下物質を提供するこ
とにある。Therefore, an object of the present invention is to provide pharmaceuticals, foods,
Another object is to provide a blood pressure-lowering substance that is safe and practical as a health food, has an ACE inhibitory effect, and is suitable for industrial production.
【0020】[0020]
【0021】本発明者らは、これらの問題を解決するた
めに種々の検討を行った結果、とうもろこしの蛋白質で
ある、水に不溶性のゼインを、前記の特開平2−240
028号公報に記載されているように、懸濁状態で直接
酵素により分解するのではなく、アンモニア等を含有す
る尿素等の蛋白質変性剤の溶液に溶解し、さらにゲル濾
過カラム等により、ゼインと尿素等の蛋白質変性剤の分
離を行い、ゼインを酵素分解を受けやすい状態にした後
に、サーモライシンなどの蛋白質分解酵素で分解したも
のに顕著なACE阻害作用があり、血圧降下剤として有
効であり、高血圧治療及び予防に利用できることを見い
出し、本発明を完成するに至った。As a result of various investigations to solve these problems, the present inventors have found that water-insoluble zein, which is a protein of corn, is used in the above-mentioned JP-A-2-240.
As described in Japanese Patent Application No. 028, the solution is not decomposed directly by an enzyme in a suspended state, but is dissolved in a solution of a protein denaturant such as urea containing ammonia and the like, and further treated with gel filtration column or the like to give zein. After separating a protein denaturing agent such as urea and making zein susceptible to enzymatic degradation, it is effective as a blood pressure lowering agent with a significant ACE inhibitory effect on what is decomposed with a proteolytic enzyme such as thermolysin. The inventors have found that they can be used for the treatment and prevention of hypertension and completed the present invention.
【0022】即ち、本発明の課題を解決するための手段
は、下記のとおりである。That is, the means for solving the problems of the present invention are as follows.
【0023】第1に、ゼインを蛋白質変性剤で溶解変性
させた後に、該変性剤を除去し、プロテアーゼにより分
解することで得られる血圧降下物質。First, a hypotensive substance obtained by dissolving and denaturing zein with a protein denaturing agent, removing the denaturing agent, and decomposing it with a protease.
【0024】第2に、ゼインを尿素で溶解変性させた後
に、尿素をゲル濾過によって除去し、サーモライシンに
より分解することで得られる血圧降下物質。Secondly, a hypotensive substance obtained by dissolving and denaturing zein with urea, removing urea by gel filtration, and decomposing it with thermolysin.
【0025】第3に、ゼインを蛋白質変性剤で溶解変性
させた後に、該変性剤を除去することで得られるプロテ
アーゼ易分解性ゼイン。Thirdly, a protease-degradable zein obtained by dissolving and denaturing zein with a protein denaturing agent and then removing the denaturing agent.
【0026】第4に、ゼインを尿素で溶解変性させた後
に、尿素をゲル濾過によって除去することで得られるプ
ロテアーゼ易分解性ゼイン。Fourth, a protease-degradable zein obtained by dissolving and denaturing zein with urea and then removing the urea by gel filtration.
【0027】第5に、ゼインを蛋白質変性剤で溶解変性
させ、容易に酵素分解を受ける性質を付加した後に、該
変性剤を除去し、プロテアーゼにより分解することで製
造する血圧降下物質の製造方法。Fifth, a method for producing a blood pressure-lowering substance produced by dissolving and denaturing zein with a protein denaturing agent, adding a property of easily undergoing enzymatic decomposition, removing the denaturing agent, and decomposing it with a protease. .
【0028】第6に、ゼインを尿素で溶解変性させ、容
易に酵素分解を受ける性質を付加した後に、尿素をゲル
濾過によって除去し、サーモライシンにより分解するこ
とで製造する血圧降下物質の製造方法。Sixth, a method for producing a blood pressure lowering substance produced by dissolving and denaturing zein with urea, adding a property of easily undergoing enzymatic decomposition, removing urea by gel filtration and decomposing with thermolysin.
【0029】第7に、ゼインを蛋白質変性剤で溶解変性
させ、容易に酵素分解を受ける性質を付加した後に、該
変性剤を除去することで製造するプロテアーゼ易分解性
ゼインの製造方法。Seventh, a method for producing a protease-degradable zein which is produced by dissolving and denaturing zein with a protein denaturing agent to add a property of easily undergoing enzymatic decomposition and then removing the denaturing agent.
【0030】第8に、ゼインを尿素で溶解変性させ、容
易に酵素分解を受ける性質を付加した後に、尿素をゲル
濾過によって除去することで製造するプロテアーゼ易分
解性ゼインの製造方法。Eighth, a method for producing a protease-degradable zein produced by dissolving and denaturing zein with urea, adding a property of easily undergoing enzymatic decomposition, and then removing urea by gel filtration.
【0031】本発明によると、ゼインを蛋白質変性剤に
より溶解変性させることで、ゼインの分子内結合が緩や
かとなり酵素作用を受け易い状態となる。According to the present invention, by dissolving and denaturing zein with a protein denaturing agent, the intramolecular bond of zein becomes gradual and the zein becomes susceptible to enzymatic action.
【0032】そして、該酵素作用を受け易い状態のもの
を、プロテアーゼによって速やかに分解することで、A
CE阻害活性を持つゼインの酵素分解物が短時間に高収
率で得られる。Then, by rapidly decomposing a substance that is susceptible to the enzyme action with a protease, A
An enzymatic decomposition product of zein having CE inhibitory activity can be obtained in a short time in a high yield.
【0033】本発明で用いる蛋白質変性剤としては、尿
素や塩酸グアニジンを使用することができる。As the protein denaturant used in the present invention, urea or guanidine hydrochloride can be used.
【0034】また、ゼインを溶解する際には、アンモニ
アや苛性ソーダを使用することができる。When dissolving zein, ammonia or caustic soda can be used.
【0035】蛋白質変性剤の除去は、特に限定されるも
のではないが、ゲルの種類などは任意で良く、Seph
adex等、分子篩が可能なゲルを用いることが出来
る。The removal of the protein denaturing agent is not particularly limited, but the kind of gel may be optional, and Seph may be used.
A gel such as adex that can be molecular sieve can be used.
【0036】なお、バッファーについても特に定めるも
のではなく、ゲルの種類に応じたバッファーを流すこと
でゼインの分離を行うことができる。The buffer is not particularly limited, and zein can be separated by flowing a buffer according to the type of gel.
【0037】分離の際のpHは、7.0〜10.0が可
能であるが、8.5付近が好ましく、pHが7.0未満
の場合はゼインの析出が起こり、pHが10.0を越え
るとゼインと色素等不純物との分離が悪くなる。The pH at the time of separation can be 7.0 to 10.0, but it is preferably around 8.5. When the pH is less than 7.0, zein is precipitated and the pH is 10.0. If it exceeds, the separation of zein from impurities such as pigments becomes worse.
【0038】また、サーモライシン等の酵素により分解
する際のpH等の条件は、使用する酵素に適した条件を
用いることができる。The conditions such as pH when decomposing with an enzyme such as thermolysin can be selected according to the enzyme used.
【0039】分解に際しては、例えば、0.5Nの水酸
化ナトリウム等を用いてpHを一定にする。Upon decomposition, the pH is kept constant by using, for example, 0.5N sodium hydroxide.
【0040】[0040]
【実施例1】Embodiment 1
【0041】とうもろこしに含まれるゼインを、溶媒抽
出、脱脂、乾燥により調製し、8M尿素−1%アンモニ
ア溶液に溶解し、ゼインを蛋白質変性させた。Zein contained in corn was prepared by solvent extraction, degreasing and drying, and dissolved in 8M urea-1% ammonia solution to denature zein.
【0042】そして、10mMのトリス塩酸緩衝液(p
H8.5)で平衡化したゲルカラム(商品名=Bio−
Gel P−2)を用いて変性剤を分離除去した。Then, 10 mM Tris-HCl buffer (p
H8.5) equilibrated gel column (trade name = Bio-
The denaturant was separated and removed using Gel P-2).
【0043】分離された白色乳液状の変性ゼインを捕集
し、該ゼインをpH8.0付近になるように0.5Nの水
酸化ナトリウムを用いてサーモライシンで約2時間分解
し、煮沸による熱変性によって酵素の失活を行ない、酵
素の活性を停止した。The separated white milky liquid modified zein was collected, and the zein was decomposed with thermolysin for about 2 hours using 0.5N sodium hydroxide so as to have a pH of about 8.0, and heat-denatured by boiling. The enzyme was deactivated and the enzyme activity was stopped.
【0044】なお、分解の際に用いる酵素は任意のもの
を用いることができるが、サーモライシンを用いた場合
には比較的高い阻害活性を持つ分解物が得られる。Any enzyme can be used for the decomposition, but when thermolysin is used, a decomposition product having a relatively high inhibitory activity can be obtained.
【0045】また、酵素の反応を停止する際には、煮沸
を行う以外にも、酵素の阻害剤などを加えても良い。When stopping the reaction of the enzyme, an enzyme inhibitor or the like may be added in addition to boiling.
【0046】得られた分解物を、Lieberman法
の山本らによる変法(日本胸部疾患学会雑誌18
(5),P297−303,1980)により、ACE
阻害活性の指標となるIC50(50%阻害の濃度、以
下IC50と略称する)を測定したところ、40μg/
ml以下であり、ここで得られた分解物は、3時間以内
の分解で十分な活性を持つものであった。The obtained decomposition product was modified by Yamamoto et al. Of the Lieberman method (Journal of the Japanese Society of Chest Diseases 18
(5), P297-303, 1980), ACE
IC50 (concentration of 50% inhibition, hereinafter abbreviated as IC50), which is an index of inhibitory activity, was measured to be 40 μg /
It was less than or equal to ml, and the decomposed product obtained here had sufficient activity even if decomposed within 3 hours.
【0047】ただし、分解時間を長くしても阻害活性は
変わらなかった。However, the inhibitory activity did not change even if the decomposition time was lengthened.
【0048】なお、以下の例でもIC50は、Lieb
erman法の山本らによる変法により測定した。In the following examples, the IC50 is Lieb
It was measured by a modified method of Yamamoto et al. of the erman method.
【0049】ここで、ゼインを変性処理することなく、
サーモライシンを用い水に懸濁した状態での直接分解法
では、分解に24時間程度かかり、且つ収量は著しく低
かった。Here, without modifying the zein,
In the direct decomposition method using thermolysin in a state of being suspended in water, decomposition took about 24 hours and the yield was remarkably low.
【0050】[0050]
【実施例2】Example 2
【0051】実施例1と同様に調製した500mgのゼ
インを、10mlの8M尿素−1%アンモニア溶液に溶
解し、蛋白質変性させた。500 mg of zein prepared in the same manner as in Example 1 was dissolved in 10 ml of 8M urea-1% ammonia solution to denature the protein.
【0052】次に、10mMのトリス塩酸緩衝液(pH
8.5)にて平衡化したBio−Gel P−2 (f
ine)カラム(φ3cm×40cm)で、ゼインから
尿素を分離除去した。Next, 10 mM Tris-HCl buffer (pH
Bio-Gel P-2 (f equilibrated in 8.5)
urea) was separated and removed from the zein using an (ine) column (φ3 cm × 40 cm).
【0053】分離されたゼインは、白い濁った乳白液と
して得られた。The isolated zein was obtained as a white cloudy opalescent liquid.
【0054】これに、1mg/mlのサーモライシン
(和光純薬製)溶液2.5mlを加えて40℃,pH
8.0で2時間分解を行った。To this, 2.5 ml of a 1 mg / ml thermolysin (manufactured by Wako Pure Chemical Industries) solution was added, and the pH was adjusted to 40 ° C.
Decomposition was performed at 8.0 for 2 hours.
【0055】分解終了後、沸騰水中で30分処理して酵
素反応を止め、凍結真空乾燥して310mgの粉末を得
た。After the completion of decomposition, the enzymatic reaction was stopped by treating in boiling water for 30 minutes and freeze-dried under vacuum to obtain 310 mg of powder.
【0056】乾燥粉末のACEに対するIC50(μg
/ml)を、実施例1と同様に、Lieberman法
の山本らによる変法により測定したところ、16.6μ
g/mlであり、充分な活性を有するものであった。IC50 (μg) for ACE of dry powder
/ Ml) was measured by a modified method of the Lieberman method by Yamamoto et al. In the same manner as in Example 1 and found to be 16.6 μm.
It was g / ml and had sufficient activity.
【0057】[0057]
【実施例3】Example 3
【0058】尿素変性ゼイン溶液からゲル濾過による尿
素の分離除去について、以下のように検討した。Separation and removal of urea from the urea-modified zein solution by gel filtration was examined as follows.
【0059】10gのゼインを400mlの8M尿素−
1%アンモニア溶液に溶解して蛋白質変性させた後、1
0mMのトリス塩酸緩衝液(pH8.5)で平衡化した
Bio−Gel P−2(fine)カラム(φ10c
m×40cm)を用いて、尿素を分離した。10 g of zein was added to 400 ml of 8M urea-
After dissolving in 1% ammonia solution to denature the protein, 1
Bio-Gel P-2 (fine) column (φ10c) equilibrated with 0 mM Tris-HCl buffer (pH 8.5).
The urea was separated using m × 40 cm).
【0060】そして、得られた各フラクションについ
て、ゼイン由来の吸光度(OD=280nm)と尿素を
測定した。Then, for each of the obtained fractions, the absorbance derived from zein (OD = 280 nm) and urea were measured.
【0061】吸光度測定には日立分光光度計(U−20
00)を用い、尿素測定には尿素窒素−テストワコー
(和光純薬製)を用いた。A Hitachi spectrophotometer (U-20
00), and urea nitrogen-Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.) was used for urea measurement.
【0062】その測定結果を、図1に示す。The measurement results are shown in FIG.
【0063】図1によると、尿素とゼインは明確に分離
していることが確認できる。From FIG. 1, it can be confirmed that urea and zein are clearly separated.
【0064】ゼインのフラクションを集めてサーモライ
シン(和光純薬製)100mgを100mlの水に溶解
して加え、40℃で2時間分解を行った。The zein fraction was collected, 100 mg of thermolysin (manufactured by Wako Pure Chemical Industries, Ltd.) was dissolved in 100 ml of water, and the mixture was decomposed at 40 ° C. for 2 hours.
【0065】その後沸騰水中で30分加熱して酵素反応
を停止し、凍結真空乾燥して、6.93gの凍結乾燥粉
末を得た。Then, the enzyme reaction was stopped by heating in boiling water for 30 minutes, and freeze-drying was carried out to obtain 6.93 g of freeze-dried powder.
【0066】[0066]
【実施例4】Embodiment 4
【0067】27.5gのゼインを、550mlの8M
尿素−1%アンモニア溶液に溶解し、一晩攪拌した後、
8000rpmで20分間遠心分離をして沈殿を取り除
き、ゲル濾過カラムによる尿素の分離除去を行った。27.5 g of zein was added to 550 ml of 8M
After dissolving in urea-1% ammonia solution and stirring overnight,
The precipitate was removed by centrifugation at 8000 rpm for 20 minutes, and urea was separated and removed using a gel filtration column.
【0068】カラム分離は、Bio−Gel P−2
(fine)をφ120mm×1000mmのカラムに
400mmの高さに充填し、10mMのトリス塩酸緩衝
液(pH8.5)にて十分に平衡化させたものにより行
った。Column separation was performed using Bio-Gel P-2.
(Fine) was packed in a column of φ120 mm × 1000 mm to a height of 400 mm and sufficiently equilibrated with 10 mM Tris-HCl buffer (pH 8.5).
【0069】カラムで分離された白濁部分を分取し、約
800mlの易分解性ゼインを得た。The cloudy portion separated by the column was collected to obtain about 800 ml of easily degradable zein.
【0070】これにサーモライシン(和光純薬製)25
0mgを250mlの水に溶解して加え、37℃で一定
時間(1、2、3または6時間)分解した。Thermolysin (manufactured by Wako Pure Chemical Industries) 25
0 mg was dissolved in 250 ml of water, added, and decomposed at 37 ° C. for a certain time (1, 2, 3 or 6 hours).
【0071】分解に際しては、0.5Nの水酸化ナトリ
ウムを用い、pH8.0に調整しながら行なった。The decomposition was carried out while adjusting the pH to 8.0 using 0.5N sodium hydroxide.
【0072】分解終了後に沸騰水中で30分処理し、凍
結真空乾燥して、各分解時間における分解物を各々得
た。After completion of the decomposition, the product was treated in boiling water for 30 minutes and freeze-dried to obtain decomposed products at each decomposition time.
【0073】得られた各分解時間における分解物につい
て、ACEに対するIC50を各々測定した。The IC50 for ACE was measured for each of the obtained decomposition products at each decomposition time.
【0074】その結果は、次のとおりであった。The results were as follows.
【0075】分解時間1時間のもののIC50は、3
1.6μg/mlであった。分解時間2時間のもののI
C50は、16.1μg/mlであった。分解時間3時
間のもののIC50は、18.3μg/mlであった。
分解時間6時間のもののIC50は、23.9μg/m
lであった。The IC50 for a decomposition time of 1 hour is 3
It was 1.6 μg / ml. I with a decomposition time of 2 hours
C50 was 16.1 μg / ml. The IC50 of the one having a decomposition time of 3 hours was 18.3 μg / ml.
The IC50 for a decomposition time of 6 hours is 23.9 μg / m
It was l.
【0076】上記のゲル分離後のゼインにおける酵素分
解時間とIC50の関係について考察すると、酵素分解
時間が2時間の場合が最もIC50が低くACE阻害活
性の高いことが判明した。When the relationship between the enzymatic decomposition time in zein after gel separation and the IC50 was examined, it was found that the IC50 was lowest and the ACE inhibitory activity was high when the enzymatic decomposition time was 2 hours.
【0077】[0077]
【実施例5】Example 5
【0078】とうもろこし蛋白ゼインの大部分を占める
α−ゼインについて、酵素分解物中のペプチドを分取し
てアミノ酸配列を決定すると共に、ACE阻害活性との
関係を調査すべく、下記に示すように実施した。Regarding α-zein, which constitutes the majority of corn protein zein, the peptides in the enzymatic degradation products were fractionated to determine the amino acid sequence and the relationship with the ACE inhibitory activity was investigated as shown below. Carried out.
【0079】70%エタノールで抽出して得た粗α−ゼ
イン100mgを、50℃にて4M尿素−1%アンモニ
ア溶液に溶解し放置後、実施例4と同様に、ゲル濾過に
より尿素を分離除去し、変性ゼインを得た。100 mg of crude α-zein obtained by extraction with 70% ethanol was dissolved in 4M urea-1% ammonia solution at 50 ° C. and allowed to stand, and then urea was separated and removed by gel filtration in the same manner as in Example 4. Then, modified zein was obtained.
【0080】該変性ゼインに、対ゼイン1/100量の
サーモライシンを加え、37℃でpH8.0に調整しな
がら3時間分解を行ない、凍結真空乾燥した。Thermolysin in an amount of 1/100 to zein was added to the modified zein, and the mixture was decomposed for 3 hours while adjusting the pH to 8.0 at 37 ° C., and freeze-dried under vacuum.
【0081】凍結真空乾燥後、分解物を100%エタノ
ールに溶かして遠心分離し、上澄みと沈殿に分けた。After freeze-drying under vacuum, the decomposed product was dissolved in 100% ethanol and centrifuged to separate into a supernatant and a precipitate.
【0082】上澄みは濃縮してF−1画分とし、沈殿は
75%エタノールに溶解、遠心分離し、その上澄みを濃
縮してF−2画分とした。The supernatant was concentrated to give an F-1 fraction, the precipitate was dissolved in 75% ethanol and centrifuged, and the supernatant was concentrated to give an F-2 fraction.
【0083】F−1及びF−2画分のIC50は、それ
ぞれ22μg/ml及び43μg/mlであった。The IC50 of the F-1 and F-2 fractions were 22 μg / ml and 43 μg / ml, respectively.
【0084】ペプチドの分画は、0.1%TFA溶液中
で日本分光社製逆相−HPLC Long C18 C
olumnを用いて行った。The fractionation of the peptide was carried out by reverse phase-HPLC Long C18 C manufactured by JASCO Corporation in a 0.1% TFA solution.
It was performed using the column.
【0085】その結果を図2に示す。The results are shown in FIG.
【0086】また、得られた個々のフラクションについ
て、ACE阻害の相対活性を求めると共に、アミノ酸配
列を決定した。Further, for each of the obtained fractions, the relative activity of ACE inhibition was determined and the amino acid sequence was determined.
【0087】各フラクションのACE阻害の相対活性及
びそれに相当するペプチドのIC−50(公知文献も参
照)を、表1[F−1画分(100%エタノール)]、
表2[F−2画分(75%エタノール)]に示す。The relative activity of ACE inhibition of each fraction and the IC-50 of the corresponding peptide (see also known literature) are shown in Table 1 [F-1 fraction (100% ethanol)],
It is shown in Table 2 [F-2 fraction (75% ethanol)].
【0088】[0088]
【表1】 [Table 1]
【0089】[0089]
【表2】 [Table 2]
【0090】これらの結果を考察すると、IC50の低
いものが多く見られ、全体のACE阻害活性を高くして
いるものと思われる。When these results are examined, many of them having a low IC50 are seen, and it is considered that the overall ACE inhibitory activity is increased.
【0091】[0091]
【実施例6】Example 6
【0092】5gのゼインを、100mlの8M尿素−
1%アンモニア溶液に溶解し、6000rpmで15分
間遠心分離をして沈殿を取り除き、得られた上澄みに対
してゲル濾過カラムによる尿素の分離除去を行った。5 g of zein was added to 100 ml of 8M urea-
It was dissolved in a 1% ammonia solution, centrifuged at 6000 rpm for 15 minutes to remove the precipitate, and the obtained supernatant was separated and removed by a gel filtration column.
【0093】カラム分離は、10mMのトリス塩酸緩衝
液で平衡化したBio−Gel P−2カラム(φ30
mm×400mm)で処理し、ゼインから尿素を分離除
去した。Column separation was carried out by Bio-Gel P-2 column (φ30, equilibrated with 10 mM Tris-HCl buffer).
mm × 400 mm) to separate and remove urea from zein.
【0094】分離されたゼイン溶液に、サーモライシン
(和光純薬製)50mgを水に溶かしたものを加え、4
0℃で2時間分解を行った。To the separated zein solution, 50 mg of thermolysin (manufactured by Wako Pure Chemical Industries) dissolved in water was added.
Decomposition was carried out at 0 ° C for 2 hours.
【0095】同様に、デナチーム(ナガセ生化学工業
(株)製)、Subtilisin(Boehringe
r Mannheim製)、パパイン(Boehrin
gerMannheim製)、プロテアーゼA(天野製
薬製)の4種類の酵素について、各々、50mgを水に
溶かしたものを分離されたゼイン溶液に加え、40℃で
2時間分解を行った。Similarly, Denateam (Nagase Seikagaku Corporation)
Subtilisin (Boehringe)
r Mannheim), Papain (Boehrin)
Germann Mannheim) and Protease A (Amano Pharmaceutical Co., Ltd.) were dissolved in water at a concentration of 50 mg, and each of them was decomposed at 40 ° C. for 2 hours.
【0096】分解に際しては、いずれも0.5Nの水酸
化ナトリウム溶液を用いてpHを調整しながら行なっ
た。The decomposition was carried out while adjusting the pH using a 0.5N sodium hydroxide solution.
【0097】この時、中和に要した0.5Nの水酸化ナ
トリウム溶液の所要量を図3に示す。At this time, the required amount of 0.5N sodium hydroxide solution required for neutralization is shown in FIG.
【0098】分解終了後に沸騰水中で30分処理し、凍
結真空乾燥して、各分解時間における分解物を各々得
た。After the decomposition, it was treated in boiling water for 30 minutes and freeze-dried to obtain decomposed products at each decomposition time.
【0099】そして、得られた各分解時間における分解
物について、ACEに対するIC50を各々測定した。Then, the IC50 for ACE was measured for each of the obtained decomposition products at each decomposition time.
【0100】その結果は、次のとおりであった。The results are as follows.
【0101】サーモライシンを用いた場合は、分解時の
pHが8.0であり、IC50が31.2μg/mlで
あった。When thermolysin was used, the pH upon decomposition was 8.0 and the IC50 was 31.2 μg / ml.
【0102】パパインを用いた場合は、分解時のpHが
7.5であり、IC50が135.0μg/mlであっ
た。When papain was used, the pH upon decomposition was 7.5 and the IC50 was 135.0 μg / ml.
【0103】デナチームを用いた場合は、分解時のpH
が8.0であり、IC50が450.7μg/mlであ
った。When Denazyme was used, the pH during decomposition
Was 8.0 and the IC50 was 450.7 μg / ml.
【0104】Subtilisinを用いた場合は、分
解時のpHが8.5であり、IC50が332.3μg
/mlであった。When Subtilisin was used, the pH at the time of decomposition was 8.5 and the IC50 was 332.3 μg.
/ Ml.
【0105】プロテアーゼAを用いた場合は、分解時の
pHが8.0であり、IC50が206.7μg/ml
であった。When Protease A was used, the pH at the time of decomposition was 8.0 and the IC50 was 206.7 μg / ml.
Met.
【0106】上記の結果を考察すると、いずれの酵素に
も活性は見られるが、サーモライシンが最も良好であっ
た。Considering the above results, activity was found in all the enzymes, but thermolysin was the best.
【0107】[0107]
【0108】本発明に係る分解物の病態動物に対する生
理活性について、下記のように試験した。The bioactivity of the hydrolyzate of the present invention against pathological animals was tested as follows.
【0109】実施例4で得たゼイン分解物(1、2、3
または6時間分解のもの)を、脳卒中易発症性高血圧自
然発症ラット(SHRSP)に対し、各々一回経口投与
し、その後経時的にラットの血圧をTail cuff
法(室町機械KK MK−1030型)により、各々測
定した。Zein degradation products (1, 2, 3) obtained in Example 4
Or 6-hour degradation) was orally administered once to stroke-prone spontaneously hypertensive rats (SHRSP), and then the blood pressure of the rats was changed over time.
Method (Muromachi Kikai KK MK-1030 type) was used for each measurement.
【0110】その結果を、図4に5匹の平均値として実
測値データを示し、図5に投与前の状態からの血圧変動
値をコントロールに対比して示した。The results are shown in FIG. 4, which shows the actual measurement data as the average value of 5 animals, and in FIG. 5, the blood pressure fluctuation value from the state before administration is shown in comparison with the control.
【0111】これらの結果を考察すると、水を与えたも
の(コントロール)の血圧は、ほぼ一定であるが、ゼイ
ン分解物を与えたものは水を与えたものに比較して最大
で20mmHgの血圧降下を示した。Considering these results, the blood pressure of the water-supplied (control) was almost constant, but the blood pressure of the zein-decomposed product was 20 mmHg at the maximum as compared with the water-supplemented one. Showed a descent.
【0112】また、実施例4で得たゼイン分解物は、2
4時間後も血圧降下作用があり、効果が長時間持続して
いることが確認できる。The zein degradation product obtained in Example 4 was 2
It can be confirmed that there is a blood pressure lowering effect even after 4 hours, and the effect continues for a long time.
【0113】従って、本発明によると、製造工程におけ
る酵素処理時間を大幅に短縮することができるため工業
的生産に適しており、得られたゼイン分解物の阻害活性
が高く、血圧降下作用が長時間持続する。Therefore, according to the present invention, the enzyme treatment time in the production process can be greatly shortened, which is suitable for industrial production, the zein degradation product thus obtained has a high inhibitory activity and a long blood pressure lowering action. Lasts for hours.
【0114】[0114]
【0115】本発明によると、医薬品、食品、または健
康食品として安全かつ実用的でACE阻害効果を有し、
工業的生産に適した血圧降下物質を提供することができ
る。According to the present invention, it is safe and practical as a pharmaceutical, food or health food and has an ACE inhibitory effect,
A blood pressure lowering substance suitable for industrial production can be provided.
【図1】ゲル濾過分離の結果を示す図FIG. 1 shows the results of gel filtration separation.
【図2】HPLCによる分離結果を示す図FIG. 2 is a diagram showing the results of separation by HPLC.
【図3】尿素除去ゼイン溶液の各種プロテアーゼによる
加水分解の際の中和に要した水酸化ナトリウム溶液の所
要量を示す図FIG. 3 is a diagram showing the required amount of sodium hydroxide solution required for neutralization during hydrolysis of urea-removed zein solution by various proteases.
【図4】ゼイン分解物の血圧に対する効果を示す図FIG. 4 is a graph showing the effect of zein decomposition products on blood pressure.
【図5】ゼイン分解物の血圧に対する効果をコントロー
ルに対する血圧変動値として示す図FIG. 5 is a graph showing the effect of zein degradation product on blood pressure as a blood pressure fluctuation value for control.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 A61K 38/00 ABU A61K 37/18 ABU ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical display area A61K 38/00 ABU A61K 37/18 ABU
Claims (8)
後に、該変性剤を除去し、プロテアーゼにより分解する
ことで得られる血圧降下物質。1. A blood pressure-lowering substance obtained by dissolving and denaturing zein with a protein denaturing agent, removing the denaturing agent, and decomposing it with a protease.
素をゲル濾過によって除去し、サーモライシンにより分
解することで得られる血圧降下物質。2. A hypotensive substance obtained by dissolving and denaturing zein with urea, removing urea by gel filtration, and decomposing it with thermolysin.
後に、該変性剤を除去することで得られるプロテアーゼ
易分解性ゼイン。3. A protease-degradable zein obtained by dissolving and denaturing zein with a protein denaturing agent and then removing the denaturing agent.
素をゲル濾過によって除去することで得られるプロテア
ーゼ易分解性ゼイン。4. A protease-degradable zein obtained by dissolving and denaturing zein with urea and then removing the urea by gel filtration.
容易に酵素分解を受ける性質を付加した後に、該変性剤
を除去し、プロテアーゼにより分解することで製造する
血圧降下物質の製造方法。5. Zein is dissolved and denatured with a protein denaturant,
A method for producing a hypotensive substance, which is produced by adding a property of easily undergoing enzymatic decomposition, then removing the denaturing agent, and decomposing with a protease.
素分解を受ける性質を付加した後に、尿素をゲル濾過に
よって除去し、サーモライシンにより分解することで製
造する血圧降下物質の製造方法。6. A method for producing a blood pressure-lowering substance produced by dissolving and denaturing zein with urea, adding a property of easily undergoing enzymatic decomposition, removing urea by gel filtration, and decomposing with thermolysin.
容易に酵素分解を受ける性質を付加した後に、該変性剤
を除去することで製造するプロテアーゼ易分解性ゼイン
の製造方法。7. Zein is dissolved and denatured with a protein denaturant,
A method for producing a protease-degradable zein, which is produced by adding a property of easily undergoing enzymatic decomposition and then removing the denaturing agent.
素分解を受ける性質を付加した後に、尿素をゲル濾過に
よって除去することで製造するプロテアーゼ易分解性ゼ
インの製造方法。8. A method for producing a protease-degradable zein, which is produced by dissolving and denaturing zein with urea, adding a property of easily undergoing enzymatic decomposition, and then removing urea by gel filtration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7077162A JPH08245694A (en) | 1995-03-09 | 1995-03-09 | Vasodepressor substance and zein capable of being easily degraded with protease and used as its production intermediate and their production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7077162A JPH08245694A (en) | 1995-03-09 | 1995-03-09 | Vasodepressor substance and zein capable of being easily degraded with protease and used as its production intermediate and their production |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH08245694A true JPH08245694A (en) | 1996-09-24 |
Family
ID=13626097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7077162A Pending JPH08245694A (en) | 1995-03-09 | 1995-03-09 | Vasodepressor substance and zein capable of being easily degraded with protease and used as its production intermediate and their production |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH08245694A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002088098A (en) * | 2000-09-11 | 2002-03-27 | Senmi Ekisu Co Ltd | Pearl oyster-originating ace-inhibitory peptide |
WO2005118619A1 (en) * | 2004-06-03 | 2005-12-15 | Kirin Beer Kabushiki Kaisha | Dipeptide exhibiting antihypertensive action |
FR2925500A1 (en) * | 2007-12-21 | 2009-06-26 | Vincience Sa | New aquaporin peptides useful in cosmetic, nutraceutical and dermatological compositions |
FR2925501A1 (en) * | 2007-12-21 | 2009-06-26 | Vincience Sa | New peptides capable of activating aquaporin protein synthesis useful in cosmetic, nutraceutical and dermatological compositions |
CN107964034A (en) * | 2017-11-13 | 2018-04-27 | 江苏大学 | The ultrasonic wave added simulation digestion method of casein active peptide and health food application |
CN114471388A (en) * | 2021-12-08 | 2022-05-13 | 大连民族大学 | Preparation method of universally applicable hydrophobic shell gel particles |
-
1995
- 1995-03-09 JP JP7077162A patent/JPH08245694A/en active Pending
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002088098A (en) * | 2000-09-11 | 2002-03-27 | Senmi Ekisu Co Ltd | Pearl oyster-originating ace-inhibitory peptide |
JP4571289B2 (en) * | 2000-09-11 | 2010-10-27 | 仙味エキス株式会社 | ACE inhibitory peptide derived from pearl oyster |
WO2005118619A1 (en) * | 2004-06-03 | 2005-12-15 | Kirin Beer Kabushiki Kaisha | Dipeptide exhibiting antihypertensive action |
JPWO2005118619A1 (en) * | 2004-06-03 | 2008-05-08 | キリンホールディングス株式会社 | Dipeptide having hypotensive action |
FR2925500A1 (en) * | 2007-12-21 | 2009-06-26 | Vincience Sa | New aquaporin peptides useful in cosmetic, nutraceutical and dermatological compositions |
FR2925501A1 (en) * | 2007-12-21 | 2009-06-26 | Vincience Sa | New peptides capable of activating aquaporin protein synthesis useful in cosmetic, nutraceutical and dermatological compositions |
WO2009106715A2 (en) * | 2007-12-21 | 2009-09-03 | Societe D'extraction Des Principes Actifs S.A. (Vincience) | Peptide derived from a protein of the aquaporin family and cosmetic and/or pharmaceutical composition containing same |
WO2009112645A1 (en) * | 2007-12-21 | 2009-09-17 | Societe D'extraction Des Principes Actifs S.A. (Vincience) | Peptide for activating aquaporin synthesis |
WO2009106715A3 (en) * | 2007-12-21 | 2009-10-22 | Societe D'extraction Des Principes Actifs S.A. (Vincience) | Peptide derived from a protein of the aquaporin family |
US8450456B2 (en) | 2007-12-21 | 2013-05-28 | Isp Investments Inc. | Activating peptide of the synthesis of aquaporins and cosmetic and/or pharmaceutical composition containing it |
CN107964034A (en) * | 2017-11-13 | 2018-04-27 | 江苏大学 | The ultrasonic wave added simulation digestion method of casein active peptide and health food application |
CN114471388A (en) * | 2021-12-08 | 2022-05-13 | 大连民族大学 | Preparation method of universally applicable hydrophobic shell gel particles |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2567582C (en) | Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates | |
JP2010520274A (en) | Methods for providing ACE inhibitory peptides from whey and the like | |
JP5892223B2 (en) | Oral anti-inflammatory agent and oral anti-inflammatory peptide | |
JP3318622B2 (en) | Prolyl endopeptidase inhibitor | |
WO2000053621A2 (en) | Synthetic complementary peptides and ophthalmologic uses thereof | |
ES2286398T3 (en) | USE OF AT LEAST ONE PEPTIDE OF THE CASEINA "ALPHA S2" WITH INHIBITING ACTIVITY OF I'ACE FOR THE PREPARATION OF MEDICINES AND FOODS. | |
Ramachandran et al. | Antihypertensive potential of bioactive hydrolysate from edible bird’s nest | |
JP5417405B2 (en) | Method for producing angiotensin converting enzyme inhibitory antihypertensive peptide composition | |
JPH08245694A (en) | Vasodepressor substance and zein capable of being easily degraded with protease and used as its production intermediate and their production | |
JPH0331298A (en) | Prolyl endopeptidase inhibitory peptide | |
CN1623600A (en) | A kind of angiotensin I converting enzyme activity inhibitor and application thereof | |
JP3088491B2 (en) | Method for producing peptide mixture | |
JP3135812B2 (en) | Angiotensin converting enzyme inhibiting peptide and method for producing the same | |
JP2010024165A (en) | Krill protein-derived angiotensin converting enzyme inhibitor | |
JP4278028B2 (en) | Peptide having inflammatory cytokine production inhibitory activity | |
WO2003055901A1 (en) | Novel peptide sy | |
JPS62169732A (en) | Hypotensor | |
JP4934369B2 (en) | Peptide having blood pressure lowering effect | |
JPH0236127A (en) | Angiotensinase inhibitor | |
JP2873327B2 (en) | Angiotensin converting enzyme inhibitor | |
JP3430176B2 (en) | Method for purifying angiotensin converting enzyme inhibitory peptide | |
JP2001261698A (en) | Angiotensin I converting enzyme inhibitor and method for producing the same | |
JP3414761B2 (en) | Oral intake | |
JP2003284551A (en) | Angiotensin I converting enzyme inhibitor | |
JP2003128694A (en) | Angiotensin converting enzyme inhibitory peptide |